Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR1 act mut||Advanced Solid Tumor||decreased response||FGFR Inhibitor (Pan)||Nintedanib||Preclinical||Actionable||In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).||22238366|
|FGFR1 act mut||Advanced Solid Tumor||sensitive||FGFR1 Inhibitor||Debio 1347||Phase I||Actionable||In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR1 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).||detail...|
|FGFR1 act mut||Advanced Solid Tumor||predicted - sensitive||FGFR Inhibitor (Pan)||Erdafitinib||Phase I||Actionable||In a Phase I trial, Balversa (erdafitinib) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363; NCT01703481).||26324363|
|FGFR1 act mut||Advanced Solid Tumor||sensitive||FGFR Inhibitor (Pan)||Ponatinib||Preclinical||Actionable||In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).||22238366|
|FGFR1 act mut||Advanced Solid Tumor||sensitive||FGFR Inhibitor (Pan)||Dovitinib||Preclinical||Actionable||In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).||22238366|
|FGFR1 act mut||breast cancer||sensitive||FGFR Inhibitor (Pan)||FIIN-1||Preclinical||Actionable||In a preclinical study, FIIN-01 inhibited Fgfr1 activation-induced proliferation and transformation of human breast epithelial cell lines in culture (PMID: 20338520).||20338520|
|FGFR1 act mut||Advanced Solid Tumor||no benefit||FGFR1 Inhibitor||Brivanib||Preclinical||Actionable||In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).||22238366|
|FGFR1 act mut||Advanced Solid Tumor||decreased response||Cediranib||Preclinical||Actionable||In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).||22238366|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04053322||Phase II||Durvalumab + Fulvestrant + Olaparib||Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)||Recruiting||1|
|NCT04096417||Phase II||Pemigatinib||Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations||Recruiting||USA||0|
|NCT04923126||Phase Ib/II||PD-0325901||SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma||Recruiting||USA||0|
|NCT02272998||Phase II||Ponatinib||Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.||Recruiting||USA||0|
|NCT02052778||Phase Ib/II||Futibatinib||A Study of TAS-120 in Patients With Advanced Solid Tumors||Completed||USA | CAN||12|
|NCT03822117||Phase II||Pemigatinib||Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)||Active, not recruiting||USA||10|
|NCT03827850||Phase II||Erdafitinib||FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)||Recruiting||1|
|NCT04092673||Phase Ib/II||eFT226||Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies||Recruiting||USA||0|
|NCT01975701||Phase II||Infigratinib||A Phase 2 Study of BGJ398 in Patients With Recurrent GBM||Completed||USA||5|